echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > PD-1 co-partner CIC:1/3 of non-small cell lung cancer patients reached complete remission

    PD-1 co-partner CIC:1/3 of non-small cell lung cancer patients reached complete remission

    • Last Update: 2021-02-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    What is CCIK? CIK cells, or cytokine-induced killer cells (Cytokine-Induced Killer, CIK) are a new type of immunoactive cells with strong CIK proliferation capacity, strong cytotoxic effect and certain immune properties.
    Because the cell expresses both CD3 and CD56 membrane protein molecules, it is also known as NK cell (natural killer cell)-like T lymphocytes, both with T lymphocytes strong anti-tumor activity, and NK cells non-MHC restrictive tumor killing advantages.
    the cell's ability to recognize tumor cells is strong, like a "cell missile", and can accurately "point" tumor cells without harming "innocent" normal cells.
    in a large-scale review of CIC cells abroad, it was also shown that 65.6% of patients with hepatocellular carcinoma received CIC cell therapy, the condition was alleviated or stabilized, the side effects were mild, and the survival rate without progression was significantly higher than that of the control group.
    , several clinical trials have shown that CIK cells not only improve the effectiveness of chemotherapy in patients, but also reduce the recurrence and metastasis of liver cancer after surgery.
    meta-analysis, which included eight randomized controlled studies, showed that CIK cells reduced postoperative recurrence rates in patients with liver cancer for one and three years and improved overall survival rates by 1-5 years.
    between May 15, 2015 and November 30, 2016, the study included 18 late-stage (mainly IV)NSCLCs, and patients voluntarily chose to receive PD-1-CIK cells (n) 7) Or treated with PD-1 (n s 11) alone, PD-L1 testing was performed on the tissues of 8 patients, 3 cases in the joint group were negative, 3 patients in the single drug group were negative in PD-L1, 2 were positive, of which 1 case was PD-L1≥50%.
    single drug group using K drug treatment, the joint group on the basis of K drug treatment, combined CPK cells.
    treatment until the disease progresses or there is unacceptable toxicity.
    study ends with safety and efficacy.
    after four years of follow-up, at the data cut-off (August 2019), there were 4 patients (57.1%) in the combined treatment group and all patients in the single-drug group (100%) died as a result of the progression of the disease.
    analysis, the mid-level follow-up time in the joint group was 28.4 months, while the mid-level follow-up time in the PD1 single-drug group was 18.6 months.
    (ORR) was 42.9% (3/7), 28.6% (2/7) patients achieved complete remission (CR), 14.3% (1/7) patients achieved partial remission (PR), 14.3% (1/7) patients were stable (SD), and DCR was 57.1 % (4/7).
    there were no CR patients in the PD1 single drug group, only 1 PR and 4 SDs.
    ORR is 9.1% (1/11) and DCR is 45.5% (5/11).
    the combined group had 28.4 months and the PD1 single-drug group had 21.7 months.
    PFS was 9.7 months in the united group and 1.3 months in the single-drug group.
    the survival of the combined treatment group did not significantly increase, the risk of death was lower than in the individual PD1 group.
    the rate of adverse events in the combined treatment group did not increase compared to the use of PD1 alone.
    will report on a forward-looking study at the upcoming WCLC meeting at the end of the month.
    This single-center, exploratory study aimed at exploring the safety and effectiveness of the domestic PD-1 inhibitor Terripri monoantigen and CIK cells in the combination therapy of PD-L1-positive NSCLC patients, and the patients in the group were randomly divided into groups A, B and C: Terriple monoantigen and CIK group (n-20), and chemotherapy groups (n-20).
    the total number of CIC cells infusions per patient exceeded 1010, and the main endpoints of the study were safety and PFS, with secondary endpoints including ORR, DCR, and OS.
    related studies also include the assessment of biomarkers and the role of PD-L1/TMB in combined therapy.
    the trial, which began in July this year, lasted 18 months.
    Immune combined therapy is more helpful in increasing the proportion of patients benefiting from single-drug therapy, and we hope that this program will provide new and potential treatment options for late-stage NSCLC therapy, thereby improving patient prognostication and quality of life.
    overall, the combination of CIK cells and PD-1 blocking antibodies has good tolerance and encouraging clinical activity, and it is expected that large sample studies will confirm this and benefit more patients at an early time.
    sources: 1.Han Y, Mu D, Liu T, Zhang H, Zhang J, Li S, Wang R, Du W, Hui Z, Zhang X, Ren X. Autologous cytokine-induced killer (CIK cell) cells enhance the clinical response to PD-1 blocking antibodies with advanced non-small cell lung: A preliminary. Thorac Cancer. 2020 Nov 4. doi: 10.1111/1759-7714.13731. Epub ahead of print. PMID: 33150733. 2.Wang Z, Liu X, Till B, Sun M, Li X, Gao Q. Combination of cytokine-induced killer cells and programmed cell death-1 blockade works synergistically to enhance therapeutic efficacy in metastatic renal cell carcinoma and non-small cell lung cancer. Front Immunol 2018; 9: 1513. 3.Liu L, Zhang W, Qi X et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012; 18 (6): 1751-9. 4. Han Y, Mu D, Liu T, et al. Autologouscytokine-induced killer (CIK) cells enhance the clinical response to PD-1blocking antibodies in patients with advanced non-small cell lung cancer: Apreliminary study[J]. Thoracic Cancer. 2020 Nov. DOI: 10.1111/1759-7714.13731.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.